Pharmaceutical Executive January 14, 2026
Key Takeaways
- Genmab is poised for growth with a diversified revenue base and three late-stage oncology assets with FDA breakthrough designations.
- Strategic acquisitions have reshaped Genmab’s profile, expanding its commercial footprint and deepening its late-stage pipeline.
- The company plans to maximize existing medicines, accelerate late-stage developments, and maintain financial discipline.
- Multiple registrational readouts are expected in 2026, setting the stage for potential launches and line extensions in 2027.
Genmab used the 44th Annual J.P. Morgan Healthcare Conference to reposition itself as it enters 2026 with a reshaped business model.
Genmab CEO Jan van de Winkel spoke during the second day at the 44th Annual J.P. Morgan Healthcare Conference on the company’s new positioning following a fundamental revison of...
Today's Sponsors
Today's Sponsor